BRAF and hairy cell leukemia: The BRAF kinase inhibitors vemurafenib and dabrafenib are effective drugs in patients with refractory and recurrent HCL, either when used in monotherapy, or in combination with CD20 antibodies or MEK inhibitors (Table 2) (8).